On 25 September 2014, the Committee for Medicinal Products for Human Use (“CHMP”) of the European Medicines Agency (“EMA”) adopted new guidelines on the evaluation of medicinal products for the treatment of irritable bowel syndrome (“IBS”) (the “New Guidelines”). The New Guidelines will come into effect on 1 April 2015.…